SMIM10L1: A Potential Drug Target and Biomarker (G100129361)

Target Name: SMIM10L1

NCBI ID: G100129361

SMIM10L1

SMIM10L1: A Potential Drug Target and Biomarker

SMIM10L1 (short for short for short interspike duration gene 1) is a gene that has been identified as a potential drug target and biomarker for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms such as memory loss, cognitive decline, and difficulty with daily activities.

SMIM10L1 is a non-coding RNA gene that has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity. The gene is expressed in the brain and is involved in the development and maintenance of the neuronal network. It is also involved in the regulation of ion channels, which are critical for the flow of electrical signals in the brain.

Previous studies have suggested that SMIM10L1 may be a drug target for several neurological disorders. For example, SMIM10L1 has been shown to be involved in the development of Alzheimer's disease, which is characterized by the progressive loss of brain cells that lead to a range of symptoms such as memory loss, cognitive decline, and difficulty with daily activities.

In addition, SMIM10L1 has also been shown to be involved in the development of Parkinson's disease, which is characterized by the progressive loss of motor neurons that lead to symptoms such as tremors and rigidity.

Another study has also suggested that SMIM10L1 may be a potential biomarker for epilepsy, a common neurological disorder that is characterized by the absence of normal electrical activity in the brain.

SMIM10L1 has also been shown to play a role in the regulation of neuronal excitability and synaptic plasticity, which are critical for the development and maintenance of the neuronal network. It is also involved in the regulation of ion channels, which are critical for the flow of electrical signals in the brain.

Previous studies have shown that SMIM10L1 may be a drug target for several neurological disorders. For example, SMIM10L1 has been shown to be involved in the development of Alzheimer's disease, which is characterized by the progressive loss of brain cells that lead to a range of symptoms such as memory loss, cognitive decline, and difficulty with daily activities.

In addition, SMIM10L1 has also been shown to be involved in the development of Parkinson's disease, which is characterized by the progressive loss of motor neurons that lead to symptoms such as tremors and rigidity.

Another study has also suggested that SMIM10L1 may be a potential biomarker for epilepsy, a common neurological disorder that is characterized by the absence of normal electrical activity in the brain.

SMIM10L1 is a gene that has been identified as a potential drug target and biomarker for several neurological disorders. Further research is needed to fully understand the role of SMIM10L1 in these conditions and to develop effective treatments.

Protein Name: Small Integral Membrane Protein 10 Like 1

The "SMIM10L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM10L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets